Search
News & Events
Wal-yan Centre welcomes Professor André Schultz as new HeadIn an exciting development for the Wal-yan Respiratory Research Centre, Professor André Schultz has been appointed as the Centre’s new Head, succeeding Professor Stephen Stick.
START Phage WA was formed to pave the way towards treating AMR infections with phage therapy in Western Australia.
Community involvement plays an integral role in guiding our research - find out how.
The Western Australian Epithelial Research Program (WAERP) is a community cohort biobank that collects and stores airway cells from the upper (nose) and lower (trachea) airways of Western Australian children and adults (1-50 years of age) undergoing non respiratory elective surgery.
The Western Australian Epithelial Research Program (WAERP) biobank is undertaking a number of research projects intended to improve the understanding and preclinical assessment of therapeutics for respiratory conditions.
Research
Lung structural and functional impairments in young children with cystic fibrosis diagnosed following newborn screening – A nationwide observational studyNon-invasive and sensitive clinical endpoints are needed to monitor onset and progression of early lung disease in children with cystic fibrosis (CF). We compared lung clearance index (LCI), FEV1, functional and structural lung magnetic resonance imaging (MRI) outcomes in Swiss children with CF diagnosed following newborn screening.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.
Research
Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trialBronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults.
Research
Antenatal creatine supplementation reduces persistent fetal lung inflammation and oxidative stress in an ovine model of chorioamnionitisChorioamnionitis is a common antecedent of preterm birth and induces inflammation and oxidative stress in the fetal lungs. Reducing inflammation and oxidative stress in the fetal lungs may improve respiratory outcomes in preterm infants. Creatine is an organic acid with known anti-inflammatory and antioxidant properties.